SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- The 53 most innovative companies in healthcare (Advisory Board)
- Delaying DOAC after colonoscopy: Weighing the risks (MDedge)
- Practice-changing takeaways from the 2026 Gut Microbiota Summit: A clinical reality check (MDLinx)
- ‘Phenomenal’ Tech May Boost Adenoma Detection in Colonoscopy (Medscape)
- CEO of America’s largest public hospital system says he’s ready to replace radiologists with AI (Radiology Business)
- OpenEvidence and Tandem Partner to Streamline Evidence-Based Prescribing and Prior Authorizations (Business Wire)
- Where GI training may fall short (Becker’s GI & Endoscopy)
- AI gut health startups are selling answers that science can’t back up (PitchBook)
